Scalper1 News
Stocks in the hepatitis C field were down Wednesday in the wake of Gilead Sciences’ (GILD) cautious forecast while potential competitor Merck hit an FDA setback. Gilead stock plunged more than 9% in early trading as multiple analysts cut their price targets in the wake of its 2015 guidance, along with comments that pointed to a high rate of discounting for Sovaldi and Harvoni to compete with AbbVie’s (ABBV) newly launched Viekira Pak. In midday Scalper1 News
Scalper1 News